FindTrial
Sign In

Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)

Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With Levofloxacin as Prophylaxis for Bacterial Infections in Immunocompromised Patients After Allogeneic Transplantation of Hematopoietic Stem Cells

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00215007
Enrollment
Unknown
Registered
2005-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2007-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogeneic Stem Cell Transplantation, Malignancy

Brief summary

The purpose of this study is to evaluate the efficacy of levofloxacin to prevent bacterial infections in the postneutropenic period in patients who have undergone allogeneic stem cell transplantation (SCT).

Interventions

DRUGLevofloxacin

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Allogeneic SCT * Postneutropenic period * Written consent

Exclusion criteria

* Fever * Antibiotic therapy * Neutropenia * Refusal by the patient

Countries

Germany

Contacts

Primary ContactIgor Wolfgang Blau, Dr.
igor.blau@charite.de0049 30 8445 4430
Backup ContactMartin Schmidt-Hieber, Dr.
martin.schmidt-hieber@charite.de0049 30 8445 4555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026